thalidomide has been researched along with Opportunistic Infections in 8 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Opportunistic Infections: An infection caused by an organism which becomes pathogenic under certain conditions, e.g., during immunosuppression.
Excerpt | Relevance | Reference |
---|---|---|
" We present a case of coinfection with disseminated HSV and VZV infection in a patient taking thalidomide for relapsed multiple myeloma." | 7.71 | Disseminated herpes simplex virus and varicella zoster virus coinfection in a patient taking thalidomide for relapsed multiple myeloma. ( Curley, MJ; Hassoun, PM; Hussein, SA, 2002) |
"Newly diagnosed patients with multiple myeloma (MM) (n=122) aged greater than 55 yr, not eligible for transplantation were randomized to receive 8 cycles of M (9 mg/m(2) /d) and P (60 mg/m(2) /d) for 4d every 6 wk (n=62) or MP and thalidomide (100 mg/d) continuously (n=60)." | 6.76 | Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group. ( Ali, R; Aydogdu, I; Beksac, M; Firatli-Tuglular, T; Goker, H; Gulbas, Z; Haznedar, R; Karakus, S; Kaya, E; Kaygusuz, I; Konuk, N; Ozdogu, H; Ozet, G; Sucak, G; Undar, L, 2011) |
"Sixty patients with advanced multiple myeloma received 2-6 monthly treatment courses combining hyperfractionated cyclophosphamide (300 mg/m2 i." | 6.71 | Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. ( Berdel, WE; Bisping, G; Dominé, N; Fenk, R; Heinecke, A; Hentrich, M; Innig, G; Kienast, J; Koch, OM; Kropff, MH; Lang, N; Mitterer, M; Ostermann, H; Straka, C; Südhoff, T, 2003) |
" We present a case of coinfection with disseminated HSV and VZV infection in a patient taking thalidomide for relapsed multiple myeloma." | 3.71 | Disseminated herpes simplex virus and varicella zoster virus coinfection in a patient taking thalidomide for relapsed multiple myeloma. ( Curley, MJ; Hassoun, PM; Hussein, SA, 2002) |
"Newly diagnosed patients with multiple myeloma (MM) (n=122) aged greater than 55 yr, not eligible for transplantation were randomized to receive 8 cycles of M (9 mg/m(2) /d) and P (60 mg/m(2) /d) for 4d every 6 wk (n=62) or MP and thalidomide (100 mg/d) continuously (n=60)." | 2.76 | Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group. ( Ali, R; Aydogdu, I; Beksac, M; Firatli-Tuglular, T; Goker, H; Gulbas, Z; Haznedar, R; Karakus, S; Kaya, E; Kaygusuz, I; Konuk, N; Ozdogu, H; Ozet, G; Sucak, G; Undar, L, 2011) |
"Sixty patients with advanced multiple myeloma received 2-6 monthly treatment courses combining hyperfractionated cyclophosphamide (300 mg/m2 i." | 2.71 | Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. ( Berdel, WE; Bisping, G; Dominé, N; Fenk, R; Heinecke, A; Hentrich, M; Innig, G; Kienast, J; Koch, OM; Kropff, MH; Lang, N; Mitterer, M; Ostermann, H; Straka, C; Südhoff, T, 2003) |
"Lenalidomide-based therapy was associated with a significant increase in risk of serious infection in patients treated compared with conventional therapy (RR = 2." | 2.58 | Immunomodulatory drugs and the risk of serious infection in multiple myeloma: systematic review and meta-analysis of randomized and observational studies. ( Chen, M; Mao, B; Wang, X; Xu, C; Zhang, X; Zhao, Y, 2018) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (25.00) | 18.2507 |
2000's | 2 (25.00) | 29.6817 |
2010's | 3 (37.50) | 24.3611 |
2020's | 1 (12.50) | 2.80 |
Authors | Studies |
---|---|
Armesto, S | 1 |
González Vela, C | 1 |
González López, MA | 1 |
Chen, M | 1 |
Zhao, Y | 1 |
Xu, C | 1 |
Wang, X | 1 |
Zhang, X | 1 |
Mao, B | 1 |
Beksac, M | 1 |
Haznedar, R | 1 |
Firatli-Tuglular, T | 1 |
Ozdogu, H | 1 |
Aydogdu, I | 1 |
Konuk, N | 1 |
Sucak, G | 1 |
Kaygusuz, I | 1 |
Karakus, S | 1 |
Kaya, E | 1 |
Ali, R | 1 |
Gulbas, Z | 1 |
Ozet, G | 1 |
Goker, H | 1 |
Undar, L | 1 |
Offidani, M | 1 |
Corvatta, L | 1 |
Polloni, C | 1 |
Gentili, S | 1 |
Brioni, A | 1 |
Visani, G | 1 |
Galieni, P | 1 |
Brunori, M | 1 |
Alesiani, F | 1 |
Catarini, M | 1 |
Centurioni, R | 1 |
Samori, A | 1 |
Blasi, N | 1 |
Ferranti, M | 1 |
Fraticelli, P | 1 |
Mele, A | 1 |
Rizzi, R | 1 |
Larocca, F | 1 |
Leoni, P | 1 |
Kropff, MH | 1 |
Lang, N | 1 |
Bisping, G | 1 |
Dominé, N | 1 |
Innig, G | 1 |
Hentrich, M | 1 |
Mitterer, M | 1 |
Südhoff, T | 1 |
Fenk, R | 1 |
Straka, C | 1 |
Heinecke, A | 1 |
Koch, OM | 1 |
Ostermann, H | 1 |
Berdel, WE | 1 |
Kienast, J | 1 |
Curley, MJ | 1 |
Hussein, SA | 1 |
Hassoun, PM | 1 |
Georghiou, PR | 1 |
Allworth, AM | 1 |
Bouza, E | 1 |
Muñoz, P | 1 |
Diaz, MD | 1 |
Vicente, T | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Phase III Trial Comparing Treatment With Melphalan+Prednisolon (MP) With Melphalan+Prednisolon+Thalidomide (MPT) for Previously Untreated Elderly Patients With Multiple Myeloma[NCT00934154] | Phase 3 | 122 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
A Pilot Study on the Efficacy of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive by Next Generation Flow[NCT03992170] | Phase 2 | 50 participants (Anticipated) | Interventional | 2018-12-31 | Recruiting | ||
A Prospective, Observational Study, to Evaluate the Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for[NCT05218603] | 100 participants (Anticipated) | Observational | 2021-11-30 | Recruiting | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
1 review available for thalidomide and Opportunistic Infections
Article | Year |
---|---|
Immunomodulatory drugs and the risk of serious infection in multiple myeloma: systematic review and meta-analysis of randomized and observational studies.
Topics: Drug Therapy, Combination; Evidence-Based Medicine; Humans; Immunocompromised Host; Immunologic Fact | 2018 |
2 trials available for thalidomide and Opportunistic Infections
5 other studies available for thalidomide and Opportunistic Infections
Article | Year |
---|---|
Opportunistic virus infections in psoriasis patients: The safer alternative of apremilast in the COVID-19 era.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID | 2020 |
Infectious complications in patients with multiple myeloma treated with new drug combinations containing thalidomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Inci | 2011 |
Disseminated herpes simplex virus and varicella zoster virus coinfection in a patient taking thalidomide for relapsed multiple myeloma.
Topics: Angiogenesis Inhibitors; Female; Herpes Simplex; Herpes Zoster; Humans; Middle Aged; Multiple Myelom | 2002 |
Thalidomide in painful AIDS-associated proctitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Humans; Male; Opportunistic Infections; Proctitis; Thalid | 1992 |
Thalidomide in patients with acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Humans; Male; Mycobacterium avium-intracellulare Infectio | 1992 |